Geraldine M Ferron
Overview
Explore the profile of Geraldine M Ferron including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
104
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ferron G, Dai Y, Semiond D
Cancer Chemother Pharmacol
. 2013 Jan;
71(3):681-92.
PMID: 23299792
Purpose: To develop a population pharmacokinetic (PK) model for cabazitaxel in patients with advanced solid tumors and examine the influence of demographic and baseline parameters. Methods: One hundred and seventy...
2.
Bapst J, Ermer J, Ferron G, Foss D, Orczyk G
Contraception
. 2006 Oct;
74(5):414-8.
PMID: 17046384
Objective: This study aimed to evaluate the pharmacokinetics, pharmacodynamics and safety of the nonsteroidal progesterone receptor agonist, tanaproget. Methods: A randomized, double-blind, placebo-controlled, sequential-group study of ascending single doses of...
3.
Plante L, Ferron G, Unruh M, Mayer P
J Reprod Med
. 2004 Dec;
49(10):825-7.
PMID: 15568407
Objective: To measure the amount of pantoprazole in human milk following its oral administration to a breast-feeding mother and to estimate human exposure. Study Design: One woman was studied over...
4.
Ferron G, Ku S, Abell M, Unruh M, Getsy J, Mayer P, et al.
Am J Health Syst Pharm
. 2003 Aug;
60(13):1324-9.
PMID: 12901033
The bioavailability of pantoprazole when administered as a suspension in sodium bicarbonate solution and as the oral tablet was studied. In an open-label, randomized, two-period crossover study, healthy fasting subjects...
5.
Ferron G, Patat A, Parks V, Rolan P, Troy S
Br J Clin Pharmacol
. 2003 Jul;
56(1):39-45.
PMID: 12848774
Aims: To evaluate potential pharmacokinetic interactions between phenobarbitone and retigabine, a new antiepileptic drug. Methods: Fifteen healthy men received 200 mg of retigabine on day 1. On days 4-32, phenobarbitone...
6.
Hermann R, Ferron G, Erb K, Knebel N, Ruus P, Paul J, et al.
Clin Pharmacol Ther
. 2003 Jan;
73(1):61-70.
PMID: 12545144
Background: The novel antiepileptic drug retigabine is the first selective M-current potassium channel opener for KCNQ2/3 and KCNQ3/5 channels. Retigabine undergoes phase II metabolism (N-glucuronidation, acetylation) exclusively and renal excretion....
7.
Metz D, Ferron G, Paul J, Turner M, Soffer E, Pisegna J, et al.
J Clin Pharmacol
. 2002 May;
42(5):512-9.
PMID: 12017345
Under normal physiological conditions, gastric acid production is controlled by a negative feedback mechanism. Proton pump inhibitors, such as pantoprazole, inhibit gastric acid secretion by irreversibly binding and inactivating luminally...
8.
Ferron G, Paul J, Fruncillo R, Richards L, Knebel N, Getsy J, et al.
J Clin Pharmacol
. 2002 Feb;
42(2):175-82.
PMID: 11831540
Retigabine, a first-in-class selective M-current potassium channel opener, is a novel antiepileptic compound currently in clinical development. The purpose of this randomized placebo-controlled study was to assess retigabine oral safety...